[1]那君艳,谢晓靖.哌拉西林钠他唑巴坦钠治疗急性加重期慢性阻塞性肺疾病的临床疗效及不良反应[J].医学信息,2024,37(15):71-74.[doi:10.3969/j.issn.1006-1959.2024.15.015]
　NA Jun-yan,XIE Xiao-jing.Clinical Efficacy and Adverse Reactions of Piperacillin Sodium and Tazobactam Sodium in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2024,37(15):71-74.[doi:10.3969/j.issn.1006-1959.2024.15.015]
点击复制

哌拉西林钠他唑巴坦钠治疗急性加重期慢性阻塞性肺疾病的临床疗效及不良反应()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年15期
页码:
71-74
栏目:
论著
出版日期:
2024-08-01

文章信息/Info

Title:
Clinical Efficacy and Adverse Reactions of Piperacillin Sodium and Tazobactam Sodium in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2024）15-0071-04
作者:
那君艳; 谢晓靖
（上饶市广信区人民医院感染科1，呼吸科2，江西 上饶 334100）
Author(s):
NA Jun-yan; XIE Xiao-jing
(Department of Infection1,Department of Respiration2,Shangrao Guangxin District People’s Hospital,Shangrao 334100,Jiangxi,China)
关键词:
哌拉西林钠他唑巴坦钠; 慢性阻塞性肺疾病; 急性加重期; 肺功能
Keywords:
Piperacillin sodium and tazobactam sodium; Chronic obstructive pulmonary disease; Acute exacerbation; Lung function
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2024.15.015
文献标志码:
A
摘要:
的 观察哌拉西林钠他唑巴坦钠治疗急性加重期慢性阻塞性肺疾病的临床疗效及不良反应。方法 选取2021年5月-2023年5月我院诊治的60例急性加重期慢性阻塞性肺疾病患者为研究对象，采用随机数字表法分为对照组（n=30）和观察组（n=30），对照组采用常规对症治疗，观察组在对照组基础上给予哌拉西林钠他唑巴坦钠治疗，比较两组临床疗效、临床症状（肺部啰音、呼吸困难、气促）改善时间、肺功能指标[呼气峰流速（PEF）、第1秒用力呼气容积（FEV1）、用力肺活量（FVC）]、血气指标[血氧分压（PaO2）、动脉血氧饱和度（SaO2）]、不良反应发生率。结果 观察组治疗总有效率为96.67%，高于对照组的83.33%（P＜0.05）；观察组肺部啰音、呼吸困难、气促改善时间均短于对照组（P＜0.05）；两组治疗后PEF、FEV1、FVC均高于治疗前，且观察组高于对照组（P＜0.05）；两组治疗后PaO2、SaO2均高于治疗前，且观察组高于对照组（P＜0.05）；观察组不良反应发生率为10.00%，与对照组的6.67%比较，差异无统计学意义（P＞0.05）。结论 哌拉西林钠他唑巴坦钠治疗急性加重期慢性阻塞性肺疾病的临床疗效确切，可缩短肺部啰音、呼吸困难、气促改善时间，改善血气指标和肺功能指标，且不会增加不良反应发生率。
Abstract:
Objective To observe the clinical efficacy and adverse reactions of piperacillin sodium and tazobactam sodium in the treatment of acute exacerbation of chronic obstructive pulmonary disease.Methods A total of 60 patients with acute exacerbation of chronic obstructive pulmonary disease diagnosed and treated in our hospital from May 2021 to May 2023 were selected as the research objects. They were divided into control group (n=30) and observation group (n=30) by random number table method. The control group was treated with conventional symptomatic treatment, and the observation group was treated with piperacillin sodium and tazobactam sodium on the basis of the control group. The clinical efficacy, improvement time of clinical symptoms (pulmonary rales, dyspnea, shortness of breath), pulmonary function indexes [peak expiratory flow (PEF), forced expiratory volume in the first second (FEV1), forced vital capacity (FVC)], blood gas indexes [partial pressure of oxygen (PaO2), arterial oxygen saturation (SaO2)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 96.67%, which was higher than 83.33% in the control group (P<0.05). The improvement time of pulmonary rales, dyspnea and shortness of breath in the observation group was shorter than that in the control group (P<0.05). After treatment, PEF, FEV1 and FVC in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). After treatment, PaO2 and SaO2 in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 10.00%, which was compared with 6.67% in the control group, the difference was not statistically significant (P>0.05).Conclusion Piperacillin sodium and tazobactam sodium is effective in the treatment of acute exacerbation of chronic obstructive pulmonary disease, which can shorten the improvement time of pulmonary rales, dyspnea and shortness of breath, improve blood gas index and lung function index, and will not increase the incidence of adverse reactions.

参考文献/References:

[1]Labaki WW,Rosenberg SR.Chronic Obstructive Pulmonary Disease[J].Ann Intern Med,2020,173(3):ITC17-ITC32.[2]李素娟,李士荣,崔立慧,等.哌拉西林他唑巴坦与头孢哌酮钠舒巴坦治疗COPD合并铜绿假单胞菌感染的疗效和安全性对比[J].现代生物医学进展,2021,21(13):2494-2498.[3]刘丽彬,王少琴,姚伟,等.哌拉西林舒巴坦钠辅助治疗老年肺炎合并COPD的疗效[J].热带医学杂志,2021,21(8):1065-1068．[4]徐雪梅,吴思颖,谢轶,等.慢性阻塞性肺疾病合并下呼吸道感染患者病原菌分布与耐药性分析[J].成都医学院学报,2017,12(2):175-181.[5]沈渠深,汪自然,戴素娟,等.头孢哌酮钠他唑巴坦钠致老年患者凝血功能异常1例[J].中国临床药学杂志,2018,27(4):284．[6]李燕,郑玲利,袁明勇,等.临床药师对抗感染治疗方案评价方法的探讨[J].药学实践杂志,2017,35(1):70-72．[7]慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组.慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)[J].国际呼吸杂志,2017,37(14):1041-1057.[8]肖文香,刘红梅,林忠贤.左氧氟沙星对老年AECOPD合并肺部感染患者免疫功能及预后的影响[J].海南医学,2020,31(2):160-163．[9]彭国茹,王宋平.慢阻肺急性加重患者痰病原菌分析与BODE指数相关性研究[J].临床肺科杂志,2021,26(9):1356-1359．[10]Cortopassi F,Gurung P,Pinto-Plata V.Chronic Obstructive Pulmonary Disease in Elderly Patients[J].Clin Geriatr Med,2017,33(4):539-552.[11]Wang L,Fan Y,Xu J,et al.The efficacy and safety of Tanreqing injection combined with western medicine for severe pneumonia: A protocol for systematic review and meta-analysis[J].Medicine (Baltimore),2020,99(35):e22010.[12]朱学艳.哌拉西林钠他唑巴坦钠联合莫西沙星治疗COPD合并急性下呼吸道感染的疗效分析[J].黑龙江医药,2020,33(2):303-305.[13]马雪,寇国先.痰热清联合哌拉西林钠他唑巴坦钠治疗AECOPD的疗效分析[J].检验医学与临床,2021,18(23):3481-3483.[14]何佳泺,姚红卫.慢性阻塞性肺疾病伴急性下呼吸道感染治疗方案探讨[J].深圳中西医结合杂志,2020,30(22):150-151.[15]闫晓慧,付艳华.定喘补虚泻肺汤联合西医常规疗法治疗慢性阻塞性肺疾病急性发作期40例[J].中医研究,2019,32(12):24-26.[16]武红莉,田瑞雪,宁兰丁,等.慢性阻塞性肺疾病患者肺部感染的影响因素分析及血清炎症因子水平变化分析[J].中华医院感染学杂志,2018,28(1):25-28.[17]蔡海彬,刘国雄,谢坚,等.盐酸氨溴索治疗慢性阻塞性肺疾病伴肺部感染的疗效观察[J].西北药学杂志,2018,33(1):113-116.[18]候诚,李秀红,王镇.布地奈德联合盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病急性加重期的效果分析[J].中国基层医药,2018,25(12):1514-1517.[19]潘小娟.哌拉西林/他唑巴坦治疗社区获得性肺炎的临床疗效分析[J].中国基层医药,2018,25(12):1501-1505.[20]陈孝辉.哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病的临床效果[J].医学信息,2022,35(13):97-99.

相似文献/References:

[1]钟雪梅,李 黎,米热班·热夏提,等.α1-抗胰蛋白酶与维吾尔族慢性阻塞性肺疾病的相关性分析[J].医学信息,2018,31(02):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
　ZHONG Xue-mei,LI Li,Mirban·rixat,et al.Correlation Analysis of α1-antitrypsin and Uygur Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(15):67.[doi:10.3969/j.issn.1006-1959.2018.02.023]
[2]陈文福.噻托溴铵治疗稳定期慢性阻塞性肺疾病的临床疗效分析[J].医学信息,2018,31(02):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
　CHEN Wen-fu.Clinical Analysis of Tiotropium Bromide in the Treatment of Stable Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(15):124.[doi:10.3969/j.issn.1006-1959.2018.02.045]
[3]吴仲东.无创机械通气用于COPD合并呼吸衰竭的疗效分析[J].医学信息,2018,31(04):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
　WU Zhong-dong.Clinical Analysis of Noninvasive Mechanical Ventilation in Patients with COPD Complicated with Respiratory Failure[J].Journal of Medical Information,2018,31(15):106.[doi:10.3969/j.issn.1006-1959.2018.04.036]
[4]龙有珠.氨茶碱联合呼吸功能训练治疗慢性阻塞性肺疾病的疗效分析[J].医学信息,2018,31(04):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
　LONG You-zhu.Effect of Aminophylline Combined with Respiratory Function Training on Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(15):127.[doi:10.3969/j.issn.1006-1959.2018.04.045]
[5]皮鑫鑫,邓 革.临床药师对1例院内感染患者的病例分析[J].医学信息,2018,31(04):188.[doi:10.3969/j.issn.1006-1959.2018.04.072]
[6]罗 倩.COPD加重期患者肺功能、血气指标及 炎症指标的变化分析[J].医学信息,2018,31(09):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
　LUO Qian.Changes of Pulmonary Function,Blood Gas and Inflammation in Patients with COPD Exacerbation[J].Journal of Medical Information,2018,31(15):114.[doi:10.3969/j.issn.1006-1959.2018.09.034]
[7]赵志国.有创-无创序贯通气疗法治疗慢性阻塞性肺疾病 引发的严重呼吸衰竭的临床研究[J].医学信息,2018,31(11):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
　ZHAO Zhi-guo.Clinical Study of Invasive Non-invasive Sequential Ventilation in Treatment of Severe Respiratory Failure Caused by Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(15):110.[doi:10.3969/j.issn.1006-1959.2018.11.034]
[8]金彦青.NPPV治疗慢性阻塞性肺疾病合并 重症呼吸衰竭的临床疗效观察[J].医学信息,2018,31(14):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
　JIN Yan-qing.Clinical Efficacy of NPPV in the Treatment of Chronic Obstructive Pulmonary Disease with Severe Respiratory Failure[J].Journal of Medical Information,2018,31(15):113.[doi:10.3969/j.issn.1006-1959.2018.14.033]
[9]张 林,白 俐.扶正化瘀胶囊对慢性阻塞性肺疾病患者炎性因子及 MMP-9、TIMP-1的影响[J].医学信息,2018,31(14):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
　ZHANG Lin,BAI Li.Effect of Fuzheng Huayu Capsule on Inflammatory Factors,MMP-9 and TIMP-1 in Patients with Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(15):152.[doi:10.3969/j.issn.1006-1959.2018.14.047]
[10]张善芳,汤 杰.穴位注射联合沙美特罗替卡松粉吸入剂治疗 慢性阻塞性肺疾病稳定期的临床疗效观察[J].医学信息,2018,31(16):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
　ZHANG Shan-fang,TANG Jie.Clinical Observation of Acupoint Injection Combined with Salmeterol and Fluticasone Powder Inhalation in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2018,31(15):131.[doi:10.3969/j.issn.1006-1959.2018.16.041]
[11]陈孝辉.哌拉西林钠他唑巴坦钠联合氨溴索治疗慢性阻塞性肺疾病的临床效果[J].医学信息,2022,35(13):97.[doi:10.3969/j.issn.1006-1959.2022.13.021]
　CHEN Xiao-hui.Clinical Effect of Piperacillin Sodium and Tazobactam Sodium Combined with Ambroxol in the Treatment of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2022,35(15):97.[doi:10.3969/j.issn.1006-1959.2022.13.021]

更新日期/Last Update: 1900-01-01